HDAC9 and T-cell non-Hodgkin lymphoma: Currently, >20 HDAC inhibitors are undergoing preclinical and clinical tests, particularly vorinostat (Zolinza) and depsipeptide (Istodax), having been approved by the Food and Drug Administration (FDA) to be used for the treatment of T-cell lymphoma (5,6).